Increasing R&D By Pharmaceutical & Biopharmaceutical Companies to Drive the Demand for Cardiac Safety Services
The report "Cardiac Safety Services Market by Type (Standalone, Integrated), Services (ECG/Holter measurement, Blood Pressure, Cardiac Imaging, Thorough QT Study, Other Services), End User (Pharmaceutical & Biopharmaceutical Companies, CRO) - Global Forecast to 2024", Estimated at USD 442 million in 2019, the cardiac safety services market is expected to reach USD 752 million by 2024, growing at a CAGR of 11.2% during the forecast period between 2019 and 2024. The growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increased outsourcing of R&D activities, and the increasing number of clinical trials are the major factors driving the growth of this industry.
In 2018, the ECG/Holter measurement segment accounted for the largest share of the cardiac safety services market.
Based on type of service, the cardiac safety services market is categorized into ECG/Holter measurement, blood pressure measurement, cardiovascular imaging, thorough QT studies, and other services. The ECG/Holter measurement segment accounted for the largest market share in 2018. This large share can be attributed to the low cost of ECG/Holter measurement services and their wide usage in measuring cardiac activity.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174488627
By type, the integrated services segment accounted for the largest market share in 2018.
Based on type, the cardiac safety services market is categorized into integrated and standalone services. The integrated services segment accounted for the largest market share in 2018. The large share of this segment can be attributed to the benefits of bundled services to oversee end-to-end developments, as compared to the specificity of standalone services.
By end user, the pharmaceutical & biopharmaceutical companies segment accounted for the largest market share in 2018.
Based on end user, the cardiac safety services market is segmented into pharmaceutical & biopharmaceutical companies and contract research organizations (CROs). The pharmaceutical & biopharmaceutical companies segment accounted for the largest market share in 2018. The large share of this segment can be attributed to factors such as the stringent regulations for drug safety and increasing R&D activities to develop new drugs.
North America was the largest regional market for cardiac safety services in 2018.
By region, the cardiac safety services market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World (RoW). In 2018, North America accounted for the largest market share, followed by Europe. This can be attributed to the presence of major pharmaceutical & biopharmaceutical companies and the large number of clinical trials performed in the region.
The prominent players operating in the cardiac safety services market include Biotrial (France), Banook Group (France & Canada), Bioclinica (US), Certara L.P. (US), Celerion, Inc. (US), ERT, Inc. (US), Laboratory Corporation of America Holdings (US), Medpace Holdings, Inc. (US), Ncardia AG (Belgium), Richmond Pharmacology (UK), PhysioStim (France), Shanghai Medicilon Inc. (China), SGS S.A. (Switzerland), BioTelemetry, Inc. (US), IQVIA (US), and Pharmaceutical Product Development LLC (US).
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062